Rubius Therapeutics, Inc. reported raising $101 Million in an initial SEC Form D filing, from an offering of $101 Million
Amount Raised
$101 Million
$101 Million sold, per SEC Form D (first sale Mar 1, 2018)
CambridgeBiotechnologyWho to call at Rubius Therapeutics, Inc., and when
A new round usually means Rubius Therapeutics, Inc. is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Rubius Therapeutics, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Rubius Therapeutics, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Rubius Therapeutics, Inc.. With Fundz connected, it knows.
Watch Fundz in Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★ 4.8/5 on G2
Company
Rubius Therapeutics, Inc.
Location
325 VASSAR STREET, SUITE 1A
Cambridge, Massachusetts, United States
About
Rubius is developing a new class of drugs, Red-Cell Therapeutics™,
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Rubius Therapeutics, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Rubius Therapeutics, Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.
